Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

404 ARTÍCULOS , VIENDO DEL 271 AL 285

Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease

Buckley RF.

Neurotherapeutics. 2021 Apr;18(2):709-727. doi: 10.1007/s13311-021-01026-5. Epub 2021 Mar 29.

Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease

Chang CH, Lin CH, Lane HY.

Int J Mol Sci. 2021 Mar 9;22(5):2761. doi: 10.3390/ijms22052761.

Ethical Considerations in Communicating Alzheimer's Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals

Wilkenfeld DA, Orbell SL, Lingler JH.

Neurotherapeutics. 2021 Apr;18(2):673-685. doi: 10.1007/s13311-021-01047-0. Epub 2021 Apr 15.

Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study

Raffin J, Rolland Y, Aggarwal G, Nguyen AD, Morley JE, Li Y, Bateman RJ, Vellas B, Barreto PS; MAPT/DSA Group.

J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):1382-1390. doi: 10.1093/gerona/glab094.

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease

Delmotte K, Schaeverbeke J, Poesen K, Vandenberghe R.

Alzheimers Res Ther. 2021 Apr 20;13(1):84. doi: 10.1186/s13195-021-00817-4.

Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins

Kulichikhin KY, Fedotov SA, Rubel MS, Zalutskaya NM, Zobnina AE, Malikova OA, Neznanov NG, Chernoff YO, Rubel AA.

Prion. 2021 Dec;15(1):56-69. doi: 10.1080/19336896.2021.1917289.

Alteration of Iron Concentration in Alzheimer's Disease as a Possible Diagnostic Biomarker Unveiling Ferroptosis

Ficiarà E, Munir Z, Boschi S, Caligiuri ME, Guiot C.

Int J Mol Sci. 2021 Apr 25;22(9):4479. doi: 10.3390/ijms22094479.

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M.

J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH.

Lancet Neurol. 2021 Jun;20(6):484-496. doi: 10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29.

Interrater agreement in dementia diagnosis: A systematic review and meta-analysis

Cerullo E, Quinn TJ, McCleery J, Vounzoulaki E, Cooper NJ, Sutton AJ.

Int J Geriatr Psychiatry. 2021 Aug;36(8):1127-1147. doi: 10.1002/gps.5499. Epub 2021 May 3.

Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity

Pyun JM, Ryu JS, Lee R, Shim KH, Youn YC, Ryoo N, Han SW, Park YH, Kang S, An SSA, Kim S.

Clin Interv Aging. 2021 Apr 30;16:749-755. doi: 10.2147/CIA.S312473. eCollection 2021.

Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences

Erickson CM, Chin NA, Coughlin DM, Conway CE, Rosario HL, Johnson SC, Clark LR.

J Am Geriatr Soc. 2021 Jul;69(7):2044-2047. doi: 10.1111/jgs.17184. Epub 2021 May 7.

Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population

Gleerup HS, Jensen CS, Høgh P, Hasselbalch SG, Simonsen AH.

EBioMedicine. 2021 May;67:103361. doi: 10.1016/j.ebiom.2021.103361. Epub 2021 May 8.

Retinal biomarkers in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis

Ge YJ, Xu W, Ou YN, Qu Y, Ma YH, Huang YY, Shen XN, Chen SD, Tan L, Zhao QH, Yu JT.

Ageing Res Rev. 2021 Aug;69:101361. doi: 10.1016/j.arr.2021.101361. Epub 2021 May 14.

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

Alawode DOT, Heslegrave AJ, Ashton NJ, Karikari TK, Simrén J, Montoliu-Gaya L, Pannee J, O Connor A, Weston PSJ, Lantero-Rodriguez J, Keshavan A, Snellman A, Gobom J, Paterson RW, Schott JM, Blennow K, Fox NC, Zetterberg H.

J Intern Med. 2021 Sep;290(3):583-601. doi: 10.1111/joim.13332. Epub 2021 Jun 26.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias